# MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer

> **NCT00072930** · PHASE2 · COMPLETED · sponsor: **MedImmune LLC** · enrollment: 150 (—)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** MEDI-522
- **BIOLOGICAL:** Docetaxel + Prednisone* + Zoledronic Acid

## Key facts

- **NCT ID:** NCT00072930
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2007-04
- **Final completion:** 2007-06
- **Target enrollment:** 150 (—)
- **Last updated:** 2008-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00072930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00072930, "MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00072930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*